Creation of nano eye-drops and effective drug delivery to the interior of the eye

Nano eye-drops are a new type of ophthalmic treatment with increased potency and reduced side effects. Compounds in conventional eye-drops barely penetrate into the eye because the cornea, located at the surface of eye, has a strong barrier function for preventing invasion of hydrophilic or large-si...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2017-03, Vol.7 (1), p.44229-44229, Article 44229
Main Authors: Ikuta, Yoshikazu, Aoyagi, Shigenobu, Tanaka, Yuji, Sato, Kota, Inada, Satoshi, Koseki, Yoshitaka, Onodera, Tsunenobu, Oikawa, Hidetoshi, Kasai, Hitoshi
Format: Article
Language:English
Subjects:
140/131
639/638/298/54/152
639/638/298/54/990
Cholesterol
Cornea
Drug delivery
Drug delivery systems
Drug efficacy
Epithelium
Eye
Fabrication
Glaucoma
Humanities and Social Sciences
multidisciplinary
Nanocrystals
Nanoparticles
R&D
Research & development
Science
Side effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nano eye-drops are a new type of ophthalmic treatment with increased potency and reduced side effects. Compounds in conventional eye-drops barely penetrate into the eye because the cornea, located at the surface of eye, has a strong barrier function for preventing invasion of hydrophilic or large-sized materials from the outside. In this work, we describe the utility of nano eye-drops utilising brinzolamide, a commercially available glaucoma treatment drug, as a target compound. Fabrication of the nanoparticles of brinzolamide prodrug increases the eye penetration rate and results in high drug efficacy, compared with that of commercially available brinzolamide eye-drops formulated as micro-sized structures. In addition, the resulting nano eye-drops were not toxic to the corneal epithelium after repeated administration for 1 week. The nano eye-drops may have applications as a next-generation ophthalmic treatment.
ISSN:2045-2322
2045-2322
DOI:10.1038/srep44229